Galectin Therapeutics Inc. Share Price
GALTGalectin Therapeutics Inc. Stock Performance
Open $2.31 | Prev. Close $2.25 | Circuit Range N/A |
Day Range $2.24 - $2.35 | Year Range $1.21 - $7.13 | Volume 14,306 |
Average Traded $2.29 |
Galectin Therapeutics Inc. Share Price Chart
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Therapeutics Inc. has a collaborative joint venture co-owned by SBH Sciences, Inc. with Galectin Sciences, LLC for the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Galectin Therapeutics Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $2.31 | $2.27 | +0.00% |
30-Apr-26 | $2.31 | $2.27 | -2.16% |
28-Apr-26 | $2.39 | $2.32 | -2.52% |
27-Apr-26 | $2.33 | $2.38 | +2.15% |
24-Apr-26 | $2.34 | $2.33 | -1.48% |
23-Apr-26 | $2.44 | $2.37 | -3.47% |
22-Apr-26 | $2.34 | $2.45 | +7.46% |